Comment submitted by B. Sachau
Posted : 04/13/2006     ID ：EPA-HQ-OAR-2006-0158-0028     Agency : EPA

Comment Period Closed
May 11,2006 11:59 PM ET

Comment submitted by Stephen A. Campbell, Senior Vice President, Regulatory Affairs, Amphastar Pharmaceuticals, Inc. for Armstrong Pharmaceuticals, Inc.
Posted : 05/14/2006     ID ：EPA-HQ-OAR-2006-0158-0029     Agency : EPA

Comment Period Closed
May 11,2006 11:59 PM ET

Comment submitted by Maureen Donahue Hardwick, International Pharmaceutical Aerosol Consortium
Posted : 05/30/2006     ID ：EPA-HQ-OAR-2006-0158-0030     Agency : EPA

Comment Period Closed
May 11,2006 11:59 PM ET

Comment submitted by Ronald J. Schott, Corporate Counsel, Wyeth
Posted : 05/30/2006     ID ：EPA-HQ-OAR-2006-0158-0031     Agency : EPA

Comment Period Closed
May 11,2006 11:59 PM ET

Comment submitted by Kristen D.W. Morris, Vice President, Government Affairs & Public Policy, Boehringer Ingelheim Pharmaceuticals, Inc
Posted : 05/30/2006     ID ：EPA-HQ-OAR-2006-0158-0032     Agency : EPA

Comment Period Closed
May 11,2006 11:59 PM ET

Comment submitted by Katherine J. Ma, General Counsel, Honeywell Speciality Chemicals
Posted : 05/30/2006     ID ：EPA-HQ-OAR-2006-0158-0033     Agency : EPA

Comment Period Closed
May 11,2006 11:59 PM ET

Comment submitted by Kristin D.W. Morris, Vice President, Government Affairs and Publlc Policy, Boehringer Ingelheim
Posted : 05/30/2006     ID ：EPA-HQ-OAR-2006-0158-0034     Agency : EPA

Comment Period Closed
May 11,2006 11:59 PM ET

Comment submitted by Fran Du Melle, Convener, US Stakeholders Group on MDI Transition
Posted : 05/30/2006     ID ：EPA-HQ-OAR-2006-0158-0035     Agency : EPA

Comment Period Closed
May 11,2006 11:59 PM ET

Comment submitted by Skadden, Arps, Slate, Meagher & Flom, LLP on behalf of GlaxoSmithKline (GSK)
Posted : 06/01/2006     ID ：EPA-HQ-OAR-2006-0158-0036     Agency : EPA

Comment Period Closed
May 11,2006 11:59 PM ET

Comment submitted by G. Molson
Posted : 06/21/2006     ID ：EPA-HQ-OAR-2006-0158-0037     Agency : EPA

Comment Period Closed
May 11,2006 11:59 PM ET

Comment submitted by Robert M. Sussman, Counsel, Latham and Watkins, LLP on behalf of Amphastar Pharmaceuticals, Inc. and Armstrong Pharmaceuticals, Inc.
Posted : 08/01/2006     ID ：EPA-HQ-OAR-2006-0158-0040     Agency : EPA

Comment Period Closed
May 11,2006 11:59 PM ET

Comment submitted by Amphastar Pharmaceuticals, Inc. and Armstrong Pharmaceuticals,
Posted : 08/21/2006     ID ：EPA-HQ-OAR-2006-0158-0041     Agency : EPA

Comment Period Closed
May 11,2006 11:59 PM ET

Placeholder for comments late CBI comments submitted by Amphastar Pharmaceuticals, Inc./Armstrong Pharmaceuticals, Inc. on August 11, 2006
Posted : 09/28/2006     ID ：EPA-HQ-OAR-2006-0158-0043     Agency : EPA

Comment Period Closed
May 11,2006 11:59 PM ET

Late Comment Submitted by Robert S. Sussman of Latham & Watkins LLP on behalf of Amphastar Pharmaceuticals, Inc./Armstrong Pharmaceuticals, Inc.
Posted : 09/28/2006     ID ：EPA-HQ-OAR-2006-0158-0044     Agency : EPA

Comment Period Closed
May 11,2006 11:59 PM ET

Late comment submitted by Amphastar Pharmaceuticals, Inc./Armstrong Pharmaceuticals, Inc. on July 31, 2006
Posted : 10/02/2006     ID ：EPA-HQ-OAR-2006-0158-0054     Agency : EPA

Comment Period Closed
May 11,2006 11:59 PM ET